Risk Factors Update Summary
- Failure to meet Nasdaq listing requirements could lead to delisting of common stock and warrants.
- Net loss increased from $22 million in 2022 to $35 million in 2023.
- Accumulated deficit rose from $143 million to $179 million by the end of 2023.
- Sold 537 shares of common stock in 2023, generating $7 million in gross proceeds.
- Limitations in Lincoln Park Purchase Agreement may hinder cash resource enhancement.
- Changes in legislation, such as the Food and Drug Omnibus Reform Act, may impact regulatory oversight.
- Implementation of the EU Patent Package may affect patent prosecution and business operations.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1828522&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.